Cargando…
Bioenergetic modulation with the mitochondria uncouplers SR4 and niclosamide prevents proliferation and growth of treatment-naïve and vemurafenib-resistant melanomas
BRAF mutations are detected in >50% of all melanomas. These mutations impair the LKB1-AMPK signaling, an important metabolic pathway associated with cell growth, proliferation and survival. Melanoma patients with BRAF mutations are usually treated with BRAF inhibitors such as vemurafenib, but res...
Autores principales: | Figarola, James L., Singhal, Jyotsana, Singhal, Sharad, Kusari, Jyotirmoy, Riggs, Arthur |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319337/ https://www.ncbi.nlm.nih.gov/pubmed/30651927 http://dx.doi.org/10.18632/oncotarget.26421 |
Ejemplares similares
-
COH-SR4 Reduces Body Weight, Improves Glycemic Control and Prevents Hepatic Steatosis in High Fat Diet-Induced Obese Mice
por: Figarola, James Lester, et al.
Publicado: (2013) -
Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics
por: Grahovac, Jelena, et al.
Publicado: (2019) -
Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics
por: Shangguan, Fugen, et al.
Publicado: (2020) -
Didymin: an orally active citrus flavonoid for targeting neuroblastoma
por: Singhal, Sharad S., et al.
Publicado: (2017) -
Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program
por: Czyz, Malgorzata, et al.
Publicado: (2019)